Kansas State University Canine Clinical Trials

 


CANINE OSTEOARTHRITIS STUDY

Accepted for publication in Canadian Veterinary Journal

  

  

ABSTRACT

As pets age, quality of life and mobility can be impacted by pain of osteoarthritis and age-related muscle atrophy (sarcopenia). The purpose of this randomized, double-blinded, placebo controlled study was to evaluate the effects of Fortetropin®, a nonthermal-pasteurized, freeze-dried, fertilized egg yolk product, on mobility in senior dogs. Mobility scores were calculated using a standardized and validated client-based survey, the Liverpool Osteoarthritis in Dogs (LOAD) questionnaire. Results showed mild, but statistically significant, improvement of the mobility scores for the treatment group at both week 6 (p= 0.03) and week 12 (p= 0.006) compared to the baseline score. No statistical improvement was noted at any time point in the placebo group or between the treatment and placebo group.

                                                                                                               
International Expert on Canine Osteoarthritis, Michael H. Jaffe, DVM, MS, CCRP, DACVS, Associate Professor, Mississippi State University College of Veterinary Medicine reviewed the study and believes that Fortetropin should be used as part of a multimodal strategy to address canine osteoarthritis.

 

"Osteoarthritis in dogs is one of the most common orthopedic conditions seen in veterinary practice. Multimodal management, with few surgical options, is the mainstay of its treatment. To combat the ongoing problem of generalized muscle atrophy due to aging and reduced pet mobility, this paper focuses on an aspect of treatment that has largely been minimally addressed. To minimize sarcopenia, and thus improve patient mobility, treatment by reduction of serum myostatin levels with Fortetropin® showed promise compared to a nutritionally similar control. Hetrick et al demonstrate a statistically significant improvement in owner assessed (LOAD) mobility scores after 6 and 12 weeks of treatment compared to a placebo supplement. Based on studies such as this, it is my opinion that use of products that inhibit myostatin levels to reduce sarcopenia, such as Fortetropin®, should be considered a valuable component of multimodal management for the treatment of canine osteoarthritis." Professor Jaffee.

 _______________________________________________________________________

 

TPLO SURGERY STUDY

A randomized, double-blind, placebo-controlled study was performed at Kansas State University to evaluate the impact of Fortetropin on muscle atrophy in 100 dogs after TPLO surgery (similar to ACL surgery in humans to repair torn ligament). The key findings of this clinical study were:

 

  • Fortetropin® prevented the loss of muscle mass in the affected and unaffected limbs.
  • Fortetropin-supplemented dogs had a more significant improvement in percentage of weight supported by the affected limb.
  • Fortetropin prevented a rise in serum myostatin levels (myostatin is a protein that prevents muscle growth.)

 

Reference:

White, Dana A., et al. "Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy." PLOS ONE 15.4 (2020): e0231306.

 

Read the Study

  Pet Nutrition